Vinpocetine attenuates the metabolic dysfunction induced by amyloid β-peptides in PC12 cells

References

• Lörinc Cs, Szász K, Kisfaludy L. The synthesis of ethyl apovincaminate. Arzneimittelforschung 1976; 26: 1907–1913
   PubMed Web of Science ®Google Scholar
• Kárpáti E., Szporny L. General and cerebral haemodynamic activity of ethyl apovincaminate. Arzneimittelforschung 1976; 26: 1908–1912
   PubMed Web of Science ®Google Scholar
• Balestreri R., Fontana L., Astengo F. A double-blind placebo controlled evaluation of the safety and efficacy of vinpocetine in the treatment of patients with chronic vascular senile cerebral dysfunction. Journal of the American Geriatrics Society 1987; 35: 425–430
   PubMed Web of Science ®Google Scholar
• Biró K., Kárpáti E., Szporny L. Protective activity of ethyl apovincaminate on ischemic anoxia of the brain. Arzneimittelforschung 1976; 26: 1918–1920
   PubMed Web of Science ®Google Scholar
• Otomo E., Atarashi J., Araki G., Ito E., Omal T., Kuzuya F., Nukada T., Ebi O. Comparison of vinpocetine with ifenprodil and dihydroergotoxine mesylate treatment and results of long treatment with vinpocetine. Current Therapeutics Research 1985; 37: 811–821
   Web of Science ®Google Scholar
• King G.A. Protective effects of vinpocetine and structurally related drugs on the lethal consequences of hypoxia in mice. Archives International Pharmacodynamics 1987; 286: 299–307
   PubMedGoogle Scholar
• Sauer D., Rischke R., Beck T., Rossberg C., Mennel H.D., Bielenberg G.W., Krieglstein J. Vinpocetine prevents ischemic cell damage in rat hippocampus. Life Sciences 1988; 43: 1733–1739
   PubMed Web of Science ®Google Scholar
• Araki T., Kogure K., Nishiaka K. Comparative neuroprotective effect of pentobarbital, vinpocetine, flunarizine and ifenprodil on ischemic neuronal damage in the gerbil hippocampus. Research Experimental Medicine 1990; 190: 19–23
   PubMed Web of Science ®Google Scholar
• Rischke R., Krieglstein J. Effects of vinpocetine on local cerebral blood flow and glucose utilization seven days after forebrain ischemia in the rat. Pharmacology 1990; 41: 153–160
   PubMed Web of Science ®Google Scholar
• Erdö S.L., Ning-Sheng C., Wolff J.R., Kiss B. Vinpocetine protects against excitotoxic cell death in primary cultures of rat cerebral cortex. European Journal of Pharmacology 1990; 187: 551–553
   PubMed Web of Science ®Google Scholar
• Miyamoto M., Murphy T.H., Schnaar R.L., Coyle J.T. Antioxidants protect against glutamate-induced cytotoxicity in a neuronal cell line. Journal of Pharmacology and Experimental Therapeutics 1989; 250: 1132–1140
   PubMed Web of Science ®Google Scholar
• Schmidt J. Comparative studies on the anticonvulsant effectiveness of nootropic drugs in kindled rats. Biomedica Biochimica Acta 1990; 49: 413–419
   PubMedGoogle Scholar
• Kaneko S., Takahashi H., Satoh M. The use of Xenopus oocytes to evaluate drugs affecting brain Ca2+ channels: effects of bifemelane and several nootropic agents. European Journal of Pharmacology 1990; 189: 51–58
   PubMed Web of Science ®Google Scholar
• Lakics V., Sebestyén M.G., Erdö S.L. Vinpocetine is a highly potent neuroprotectant against veratridine-induced cell death in primary cultures of rat cerebral cortex. Neuroscience Letters 1995; 185: 127–130
   PubMed Web of Science ®Google Scholar
• Tretter L., Adam-Vizi V. The neuroprotective drug vinpocetine prevents veratridine-induced [Na+]i and [Ca2+]i rise in synaptosomes. NeuroReport 1998; 9: 1849–1853
   PubMed Web of Science ®Google Scholar
• Kaneko S., Sugimura M., Inoue T., Satoh M. Effects of several cerebroprotective drugs on NMDA channel function: evaluation using Xenopus oocytes and [3H]MK-801 binding. European Journal of Pharmacology 1991; 207: 119–128
   PubMed Web of Science ®Google Scholar
• Kiss B., Cai N.S., Erdö S.L. Vinpocetine preferentially antagonises quisqualate/AMPA receptor responses: evidence from release and ligand binding studies. European Journal of Pharmacology 1991; 209: 109–112
   PubMed Web of Science ®Google Scholar
• Krieglstein J., Rischke R. Vinpocetine increases the neuroprotective effect of adenosine in vitro. European Journal of Pharmacology 1991; 205: 7–10
   PubMed Web of Science ®Google Scholar
• Orviský E, Soltés L, Stančiková M. High-molecular-weight hyaluronan- a valuable tool in testing the antioxidative activity of amphiphilic drugs stobadine and vinpocetine. Pharmacological and Biomedical Analysis 1997; 16: 419–424
   PubMed Web of Science ®Google Scholar
• Uchiyama-Tsuyuki Y., Okuyama S., Araki H. VA-045, anovel apovincamic acid derivative atteneuates neuronal injury induced by hypoxia or by excitatory amino acids in cultures of rat cortices. Life Sciences 1996; 59: 1571–1578
   PubMed Web of Science ®Google Scholar
• Behl C., Davis J., Cole G.M., Schubert D. Vitamin E protects nerve cells from amyloid β protein toxicity. Biochemical and Biophysical Research Communications 1992; 186: 944–950
   PubMed Web of Science ®Google Scholar
• Behl C., Davis J.B., Lesley R., Schubert D. Hydrogen peroxide mediates amyloid β protein toxicity. Cell 1994; 77: 817–827
   PubMed Web of Science ®Google Scholar
• Sano M., Ernesto C., Thomas R.G., Klauber M.R., Schafer K., Grundman M., Woodbury P., Growdon J., Cotman D.W., Pfeiffer E., Schneider L.S., Thal L.J. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimers disease. New England Journal of Medicine 1997; 336: 1216–1222
   PubMed Web of Science ®Google Scholar
• Selkoe D.J. The molecular pathology of Alzheimer's disease. Neuron 1993; 6: 487–498
   Web of Science ®Google Scholar
• Behl C., Trapp T., Skutella T., Holsboer F. Protection against oxidative stress-induced neuronal cell death-a novel role for RU486. European Journal of Neuroscience 1997; 9: 912–920
   PubMed Web of Science ®Google Scholar
• Pereira C., Santos M.S., Oliveira C.R. Mitochondrial function impairment induced by amyloid β-peptide on PC12 cells. NeuroReport 1998; 9: 1749–1755
   PubMed Web of Science ®Google Scholar
• Pereira C., Santos M.S., Oliveira C.R. Involvement of oxidative stress on the impairment of energy metabolism induced by Aβ-peptides on PC12 cells. Protection by antioxidants. Neurobiology of Disease 1999; 6: 209–219
   PubMed Web of Science ®Google Scholar
• Mosmann T. Rapid colorimetric assay for cellular growth and survival. Journal of Immunological Methods 1983; 65: 55–63
   PubMed Web of Science ®Google Scholar
• Royall J.A., Ischiropoulos H. Evaluation of 2′,7′-dichlorofluorescin and dihydrorhodamine 123 as fluorescent probes for intracellular H2O2in cultured endothelial cells. Archives of Biochemistry and Biophysics 1993; 302: 348–355
   PubMed Web of Science ®Google Scholar
• Ragan C.I., Wilson M.T., Darley-Usmar V.M., Lowe P.N. Subfractionation of mitochondria, and isolation of the proteins of oxidative phosphorylation. Mitochondria, a Pratical Approach, V.M. Darley-Usmar, D. Rickwood, M.T. Wilson. IRL Press, London 1987; 79–112, In
   Google Scholar
• Tisdale H.D. Preparation and properties of succinic-cytochrome c reductase (complex II and III). Methods in Enzymology 1967; 10: 213–215
   Google Scholar
• Brautigan D.L., Ferguson-Miller S., Margoliash E. Mitochondrial cytochrome c: preparation and activity of native and chemically modified cytochrome c. Methods in Enzymology 1978; 53: 128–164
   PubMedGoogle Scholar
• Kooy N.W., Royall J.A., Ischiropoulos H. Oxidation of 2′,7′-dichlorofluorescin by peroxynitrite. Free Radical Research 1997; 27: 245–254
   PubMed Web of Science ®Google Scholar
• Hu J., el-Sakahani E.E. Beta-amyloid activates nitric oxide synthase in a neuronal clone. NeuroReport 1993; 6: 760–762
   Google Scholar
• Hensley K., Carney J.M., Mattson M.P., Aksenova M., Harris M., Wu J.F., Foyd R., Butterfield D.A. A model for β-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer's disease. Proceedings of the National Academy of Sciences of USA 1994; 91: 3270–3274
   PubMed Web of Science ®Google Scholar
• Butterfield D.A., Hensley K., Harris M., Mattson M.P., Carney J. β-Amyloid peptide free radical fragments initiate synaptosomal lipoperoxidation in a sequence-specific fashion: implications to Alzheimer's disease. Biochemical and Biophysical Research Communications 1994; 200: 710–715
   PubMed Web of Science ®Google Scholar
• Mattson M.P., Cheng B., Davis D., Bryant K., Lieberburg I., Rydel R.E. β-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. Journal of Neuroscience 1992; 12: 379–389
   Web of Science ®Google Scholar
• Mattson M.P., Barger S.W., Cheng B., Lieberburg I., Smith-Swintosky V.L., Rydel R.E. β-amyloid precursor protein metabolites and loss of neuronal Ca2+ homeostasis in Alzheimer's disease. Trends in Neuroscience 1993; 16: 409–414
   PubMed Web of Science ®Google Scholar
• Goodman Y., Steiner M.R., Steiner S.M., Mattson M.P. Nordihydroguaiaretic acid protects hippocampal neurons against amyloid β-peptide toxicity, and attenuates free radical and calcium accumulation. Brain Research 1994; 654: 171–176
   PubMed Web of Science ®Google Scholar
• Fukuyama R., Wadhwani K.C., Galdzicki Z., Rapoport S.I., Ehrenstein G. β-Amyloid polypeptide increases calcium-uptake in PC12 cells: a possible mecahanism for its cellular toxicity in Alzheimer's disease. Brain Research 1994; 667: 269–272
   PubMed Web of Science ®Google Scholar
• Yallampalli S., Micci M.-A., Taglialatela G. Ascorbic acid prevents β-amyloid-induced intracellular calcium increase and cell death in PC12 cells. Neuroscience Letters 1998; 25: 105–108
   Google Scholar
• Mcintosh T.K., Saatman K.E., Raghupathi R. Calcium and the pathogenesis of traumatic CNS injury: cellular and molecular mechanisms. The Neuroscientist 1997; 3: 169–175
   Web of Science ®Google Scholar